Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NOVAVAX INCNVAX · Entity 4632 | Director | June 17, 2021 | June 22, 2021 |
| UNITED STATES ANTIMONY CORPUAMY · Entity 183 | Director · Chairman & CEO | August 28, 2026 | August 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NOVAVAX INC
Report date June 17, 2021 · Filed June 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,549 |
Reported balance
After 2021-06-17 transaction · row 1
1 source rowRow 1 · 2021-06-17 · Exercise / conversion · Acquired 3,450 · Balance 19,549 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-06-17 · Exercise / conversion · Disposed 3,450 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2: In connection with the reporting person's departure from the Board of Directors (the "Board"), the Board accelerated the vesting of 3,450 restricted stock units subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), to June 17, 2021 from June 25, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2: In connection with the reporting person's departure from the Board of Directors (the "Board"), the Board accelerated the vesting of 3,450 restricted stock units subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), to June 17, 2021 from June 25, 2021.
UNITED STATES ANTIMONY CORP
Report date August 28, 2026 · Filed August 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,590,028 |
Reported balance
After 2026-08-28 transaction · row 1
1 source rowRow 1 · 2026-08-28 · Purchase · Acquired 20,000 · Balance 2,590,028 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 13, 2018 Filed Dec 14, 2018 21:49 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to buy) · Derivative | 90,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001209191-18-062753 · doc4.xml · derivative · entry 1 EVANS GARY C · CIK 0001191410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2028-12-13 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended, will vest one (1) year from the December 13, 2018 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 21:12 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to buy) · Derivative | 80,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001209191-17-066315 · doc4.xml · derivative · entry 1 EVANS GARY C · CIK 0001191410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2027-12-15 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended, will vest one (1) year from the December 15, 2017 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 20:16 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to buy) · Derivative | 80,000 | $0.00 Strike: $1.38 | $0.00 |
DisclosureSEC source: 0001209191-17-021706 · doc4.xml · derivative · entry 1 EVANS GARY C · CIK 0001191410 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2027-03-16 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan will vest one (1) year from the March 16, 2017 grant date subject to continued service on the Company's Board of Directors through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.